This press release contains forward-looking statements. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements relating to the potential launch and commercialization of, and potential approval by the FDA of, INTERCEPT-treated plasma to treat TTP, potential orphan drug exclusivity for INTERCEPT-treated plasma to treat TTP if approved by the FDA, the commercial potential for INTERCEPT-treated plasma to treat TTP, and Cerus’ expectations regarding the success and significance of the BSI and American Red Cross partnerships. These forward-looking statements are based upon Cerus’ current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with the uncertain, costly and time-consuming product development process, risks associated with obtaining FDA regulatory approval for INTERCEPT-treated plasma, risks related to the commercial prospects for INTERCEPT-treated plasma, the risks that Cerus, the American Red Cross and BSI may not fulfill their respective obligations under the partnership agreements or that the partnership agreements may not be maintained, risks related to Cerus’ need for additional capital, including the risk that the sufficient additional funding Cerus requires for the further development of INTERCEPT-treated plasma for approval in the US may not be obtained, and other risks detailed in the Cerus' filings with, the Securities and Exchange Commission (SEC), including in Cerus' annual report on Form 10-Q for the quarter ended June 30, 2012, filed with the SEC on August 8, 2012. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Cerus does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
Cerus To Partner With American Red Cross And Blood Systems Incorporated To Commercialize INTERCEPT Plasma For Thrombotic Thrombocytopenic Purpura (TTP) Orphan Indication
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts